Holen Sie sich die Stockscreener-App
12.03
0.91%
-0.09
Schlusskurs vom Vortag:
$12.12
Offen:
$12.47
24-Stunden-Volumen:
284.00K
Relative Volume:
0.10
Marktkapitalisierung:
$1.37B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-284.08M
KGV:
-6.7584
EPS:
-1.78
Netto-Cashflow:
$-234.65M
1W Leistung:
-0.83%
1M Leistung:
-0.50%
6M Leistung:
+71.82%
1J Leistung:
+17.98%
1-Tages-Spanne:
$11.98
$12.47
1-Wochen-Bereich:
$11.53
$12.47
52-Wochen-Spanne:
$3.72
$12.97
Cogent Biosciences Inc Stock (COGT) Company Profile
Firmenname
Cogent Biosciences Inc
Sektor
Branche
Telefon
617-945-5576
Adresse
275 WYMAN STREET, WALTHAM
Vergleichen Sie COGT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
12.01 | 1.69B | 0 | -284.08M | -234.65M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.05 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.90 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
444.53 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
686.29 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
312.00 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-11 | Herabstufung | Needham | Buy → Hold |
| 2024-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Eingeleitet | Citigroup | Buy |
| 2023-12-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-12-08 | Eingeleitet | JP Morgan | Overweight |
| 2023-04-28 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-06-28 | Eingeleitet | Guggenheim | Buy |
| 2021-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-06-09 | Fortgesetzt | Jefferies | Buy |
| 2020-12-23 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Cogent Biosciences Inc Aktie (COGT) Neueste Nachrichten
Cogent Biosciences Inc. Inches Above Key Support — Safe to HoldIndex Update & Daily Growth Stock Investment Tips - thegnnews.com
Cogent Biosciences, Inc. $COGT Stock Position Lessened by XTX Topco Ltd - MarketBeat
Cogent Biosciences Inc. Price Targets Raised After ReboundJuly 2025 Technicals & Risk Controlled Swing Alerts - kangso.co.kr
Is Cogent Biosciences Inc. a good ESG investment2025 Volatility Report & Community Driven Trade Alerts - thegnnews.com
What makes Cogent Biosciences Inc. stock price move sharplyJuly 2025 Selloffs & Technical Confirmation Trade Alerts - Newser
Backtesting results for Cogent Biosciences Inc. trading strategiesRisk Management & Real-Time Buy Signal Alerts - Newser
Can volume confirm reversal in Cogent Biosciences Inc.Weekly Trade Review & Long-Term Safe Investment Plans - Newser
Live market analysis of Cogent Biosciences Inc.2025 Geopolitical Influence & Consistent Growth Equity Picks - Newser
Can technical indicators confirm Cogent Biosciences Inc.’s reversalJuly 2025 Action & Community Consensus Stock Picks - Newser
What machine learning models say about Cogent Biosciences Inc.2025 Earnings Surprises & Technical Pattern Recognition Alerts - Newser
How to build a custom watchlist for Cogent Biosciences Inc.2025 Analyst Calls & Consistent Profit Trading Strategies - Newser
When is the best time to buy Cogent Biosciences Inc. stockEarnings Overview Report & Safe Entry Point Identification - Newser
Real time breakdown of Cogent Biosciences Inc. stock performanceJuly 2025 Drop Watch & Daily Profit Maximizing Trade Tips - Newser
Is There Enough Volume to Lift Cogent Biosciences Inc.Rate Hike & Daily Chart Pattern Signal Reports - sundaytimes.kr
XTX Topco Ltd Cuts Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Using data filters to optimize entry into Cogent Biosciences Inc.2025 Price Action Summary & Free Long-Term Investment Growth Plans - Newser
Knott David M Jr Takes $1.28 Million Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Drawdown in Cogent Biosciences Inc. May Be Nearing EndTrade Exit Summary & Daily Oversold Stock Bounce Ideas - kangso.co.kr
Do Rising R&D Losses at Cogent Biosciences (COGT) Reflect Strategic Vision or Escalating Risk? - simplywall.st
Resistance Break Could Fuel Cogent Biosciences Inc. Rally2025 Top Decliners & Verified Chart Pattern Trade Signals - beatles.ru
Wedbush Lowers Earnings Estimates for Cogent Biosciences - MarketBeat
Leerink Partnrs Has Pessimistic Outlook of COGT Q3 Earnings - MarketBeat
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference - The Globe and Mail
Cogent Biosciences Reports First Quarter 2025 Financial Results - The Globe and Mail
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - The Globe and Mail
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing - The Globe and Mail
Cogent Biosciences to Participate in the Guggenheim Biotech Conference - The Globe and Mail
Q3 EPS Forecast for Cogent Biosciences Raised by Analyst - MarketBeat
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Cogent Biosciences (NASDAQ:COGT) Stock - MarketBeat
Wedbush Reduces Earnings Estimates for Cogent Biosciences - MarketBeat
Cogent Biosciences price target lowered to $21 from $22 at H.C. Wainwright - MSN
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $30.00 - Defense World
HC Wainwright Issues Pessimistic Forecast for Cogent Biosciences (NASDAQ:COGT) Stock Price - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
How Investors Are Reacting To Cogent Biosciences (COGT) Widening Losses in Q2 and First Half 2025 - simplywall.st
Leerink Partnrs Issues Negative Outlook for COGT Earnings - Defense World
Cogent Biosciences shares fall 1.64% intraday after Cogent Communications misses Q2 net loss per share estimates. - AInvest
Cogent Biosciences Reports Increased Losses Amidst Ongoing Development - The Globe and Mail
Cogent Biosciences Reports Positive Trial Results, Updates Financial Position - AInvest
Scotiabank Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17 - 富途牛牛
Needham Maintains Cogent Biosciences(COGT.US) With Hold Rating - 富途牛牛
COGT Stock Rating Maintained by HC Wainwright, Price Target Lowe - GuruFocus
Cogent Biosciences (COGT) Price Target Revised by Analyst - GuruFocus
Decoding Cogent Biosciences Inc (COGT): A Strategic SWOT Insight - GuruFocus
Promising Pipeline and Financial Stability Drive Buy Rating for Cogent Biosciences - TipRanks
Cogent Biosciences: KDJ Golden Cross and Bullish Marubozu Indicators Detected - AInvest
Cogent Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cogent Biosciences Reports Recent Business Highlights and Secon - GuruFocus
Cogent Biosciences' Q2 net loss widens as costs mount - TradingView
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results - GlobeNewswire
BRIEF-Cogent Biosciences Q2 Operating Expenses USD 75.581 Million - TradingView
Finanzdaten der Cogent Biosciences Inc-Aktie (COGT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cogent Biosciences Inc-Aktie (COGT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pinnow Cole | Chief Commercial Officer |
Jan 14 '25 |
Buy |
7.60 |
43,750 |
332,412 |
45,848 |
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):